EDSA today
$1.94-$0.14 (-6.73%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bullish
15 minStrong Bullish
5 minSymmetric Triangle
Daily trend turns up above $2.86
Key levels
Resistance$2.86
Resistance$2.46
Support$1.85
Support$1.41
Latest news & SEC filings
DealEdesa Biotech signs exclusive licensing deal with KYORIN for Paridiprubart in Japan
DealEdesa Biotech licenses paridiprubart rights in Japan to Kyorin Pharmaceutical in $140M+ deal
All EDSA news →About Edesa Biotech
Edesa Biotech is a clinical-stage biopharmaceutical company that creates therapies for conditions involving inflammation and the immune system. Its pipeline includes drug candidates for skin disorders such as vitiligo and allergic contact dermatitis, and for lung conditions like acute respiratory distress syndrome. The company operates in Canada and the United States, focusing on areas with limited treatment options.
Based on the company's 10-K filed Dec 12, 2025.
Nasdaq · Healthcare
Edesa Biotech, Inc. (EDSA)
What Is the Price Target for EDSA?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is EDSA a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for EDSA.
Start Free Trial →Is EDSA Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
0
Moat Score
NONE
2/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with EDSA?
Insider Signal
BUYING
5 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Nijhawan Pardeep | director officer 10% owner | Buy | 18,677 | - | Nov 4, 2026 |
| Nijhawan Pardeep | director officer 10% owner | Buy | 27,602 | - | Oct 28, 2026 |
| Nijhawan Pardeep | director officer 10% owner | Buy | 6,893 | - | Oct 5, 2026 |
| Nijhawan Pardeep | director officer 10% owner | Buy | 5,714 | - | Sep 1, 2026 |
| Nijhawan Pardeep | director officer 10% owner | Buy | 1,671 | - | Jun 1, 2026 |
| Marshall Patrick | director | Buy | 19,000 | - | May 27, 2026 |
| MacDonald Sean Arthur | director | Buy | 19,000 | - | May 27, 2026 |
| Chypyha Joan | director | Buy | 19,000 | - | May 27, 2026 |
| Weiler Peter J. | officer | Buy | 64,609 | - | May 27, 2026 |
| Brooks Michael J | officer | Buy | 64,609 | - | May 27, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →EDSA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for EDSA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for EDSA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:51:26 | $1.92 | 3,000 | $$6K | BUY |
| 20:51:26 | $1.92 | 1,900 | $$4K | BUY |
| 20:44:15 | $1.90 | 4,500 | $$9K | BUY |
| 20:40:06 | $1.88 | 3,799 | $$7K | BUY |
| 20:40:06 | $1.88 | 3,799 | $$7K | BUY |
5 dark pool trades shown · $$32K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About EDSA
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for EDSA. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$EDSA: Adage Capital Management, L.P. filed a Schedule 13G on Thu Nov 12 disclosing beneficial ownership of 1,100,000 common shares, 7.83% of the company, including 550,000 shares issuable upon exerci...
Join 3,500+ traders discussing EDSA in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Edesa Biotech, Inc. (EDSA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →EDSA — frequently asked questions
What is EDSA stock price today?
Edesa Biotech, Inc. (EDSA) is at $1.94, down 6.73% (-$0.14) at the Nov 13, 2026 close.
Why is EDSA stock moving today?
Latest EDSA news — Nov 9, 2026: Edesa Biotech signs exclusive licensing deal with KYORIN for Paridiprubart in Japan · Nov 9, 2026: Edesa Biotech licenses paridiprubart rights in Japan to Kyorin Pharmaceutical in $140M+ deal
What do analysts rate EDSA?
Analyst ratings for EDSA: 2 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did EDSA beat earnings?
EDSA last reported on Aug 13, 2026: EPS -$0.60 vs -$0.43 expected — a miss of 37.9%.
Does EDSA pay a dividend?
EDSA does not currently pay a dividend.
What are EDSA support and resistance levels?
Support: $1.85, $1.41, $0.72. Resistance: $2.46, $2.86, $3.84.
What are insiders doing with EDSA?
Insider activity: BUYING, 5 buys and 0 sells in the last 90 days.
What is the latest news on EDSA?
Nov 9, 2026: Edesa Biotech signs exclusive licensing deal with KYORIN for Paridiprubart in Japan · Nov 9, 2026: Edesa Biotech licenses paridiprubart rights in Japan to Kyorin Pharmaceutical in $140M+ deal